PHAT
What one share of Phathom Pharmaceuticals holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB.
Phathom Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.06 |
|---|---|
| Profit | −$1.27 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.47 |
| Cash and investments | $2.28 |
| Debt | $2.06 |
| Book value | −$4.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$0.21 | — | −$0.17 | — | −$0.19 |
| 2019 | — | −$22.45 | $0.01 | −$3.22 | — | — |
| 2020 | — | −$3.88 | $0.03 | −$2.13 | — | $6.81 |
| 2021 | — | −$3.89 | $0.01 | −$4.02 | — | $2.36 |
| 2022 | $0.00 | −$5.05 | $0.03 | −$3.77 | — | −$1.80 |
| 2023 | $0.01 | −$3.93 | $0.03 | −$2.71 | — | −$1.26 |
| 2024 | $0.87 | −$5.29 | $0.00 | −$4.22 | — | −$3.70 |
| 2025 | $2.40 | −$3.03 | $0.00 | −$2.29 | — | −$6.14 |